百隆東方(601339.SH):越南百隆員工到崗率90%左右、實際產能已恢復接近90%
格隆匯11月1日丨百隆東方(601339.SH)公佈,根據越南國內最新調整的疫情防控政策,自2021年10月30日起,越南國內逐步放開“三就地”政策。越南百隆現有100萬紗錠生產能力,產能約佔公司全部產能的60%。截至公吿發布之日,越南百隆員工到崗率90%左右;實際產能已恢復接近90%,員工新冠疫苗接種率已達90%。因受越南國內疫情影響,越南百隆實施“三就地”政策以來,減少的產量約佔公司全年產量的8%左右。
未來,公司仍將在確保所有在越員工身體健康的首要前提下,有序恢復全面生產,彌補減產損失,確保產品交期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.